SPONSORSHIP ALLIANCE PARTNER NEWS

Sponsorship Alliance Partner News

News from Our Sponsorship Alliance Partners

July 2022

viewray

Henry Ford Health Becomes the First Center to Treat Patients with ViewRay's MRIdian A3i System

New MRIdian A3i features will enable the Henry Ford team to streamline on-table workflow, reduce treatment times, and expand clinical utility to brain treatments.


Click to Read More


Shin-Matsudo Central General Hospital Select's ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Expand Access to Precision Radiation Therapy

Shin-Matsudo Central General Hospital has purchased a MRIdian MRI-guided radiation therapy system for installation at Shin-Matsudo Accuracy Radiation Therapy (SMART) Center in Japan. This is the third MRIdian system in Japan intended to help address an unmet need with a growing population and an increasing rate of cancer patientsin Toukatsu.


Click to Read More


VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services

Represents Second VA Hospital to Offer MRIdian MRI-guided Radiation Therapy Cancer Treatment Directly to Veterans.


Click to Read More

refleXion

Telix and RefleXion Expand Partnership for Prostate Cancer Treatment

Telix and RefleXion announced the signing of a co-development and co-commercialization agreement, to expand the use of Telix’s PSMA-targeted prostate cancer PET imaging agent with the RefleXion® biology-guided radiotherapy (BgRT) platform to guide external-beam radiotherapy in real-time.

Click to Read More


A ‘TOP GUN’ Battles Prostate Cancer

Retired Navy commander, Michael “Bing” Crosby, recounts his journey with prostate cancer: from diagnosis to founding the Veterans Prostate Cancer Awareness (VPCa) organization. In 2022, Crosby joined RefleXion Medical’s Patient Advocacy Advisory Board (PAAB) to offer guidance on prostate cancer based on his own prostate cancer journey and his advocacy work.

Click to Read More


RefleXion Holds Cancer Symposium on Tumor Biology for Personalized Radiotherapy

RefleXion was thrilled to gather renowned thought leaders for an evening of innovative scientific discussion at its Sam Gambhir Memorial Learning Center. This meeting discussed innovative approaches to further personalizing radiotherapy treatment including PULSAR, RadScopal and biology-guided radiotherapy (BgRT). To learn more about RefleXion's BgRT, please visit us at reflexion.com

Click to Read More

June 2022

viewray

UCI Health Adopts ViewRay® MRIdian® MRI-Guided Radiation Therapy System

MRIdian will be the First MRI-Guided Radiation Therapy System at the UCI Chao Family Comprehensive Cancer Center facility opening in late 2023.

Click to Read More


ViewRay Named “Best Overall MedTech Company” in 2022 MedTech Breakthrough Awards Program

ViewRay, Inc. (NASDAQ: VRAY) today announced that it has been named “Best Overall MedTech Company” in the sixth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global health and medical technology market.

Click To Read More

Zap Surgical

Baptist Health South Florida to Acquire ZAP Surgical’s ZAP-X Gyroscopic Radiosurgery Platform for Advanced Brain Tumor Treatments

Baptist Health South Florida will soon acquire the ZAP-X® Gyroscopic Radiosurgery® platform for cranial stereotactic radiosurgery (SRS). The ZAP-X will be used by Miami Neuroscience Institute, in collaboration with Miami Cancer Institute, both part of Baptist Health South Florida, dedicated to offering the most innovative and advanced techniques to diagnose and treat brain disorders and tumors. Installation of the ZAP-X platform is expected to commence in late 2022.

Click to Read More

ZAP Surgical’s CEO and Stanford Neurosurgeon Receives Prestigious Janeway Medal, Recognized for Pioneering and Continued Advancement of Radiosurgical Brain Tumor Therapy

Dr. John R. Adler, CEO of ZAP and Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University received the esteemed Janeway Medal at the annual American Radium Society (ARS) meeting in Scottsdale, Arizona. In addition to receiving the medal, Dr. Adler also delivered the Janeway Lecture entitled “Sometimes an Entrepreneur, Always a Doctor” to the meeting’s clinical delegation.

Click to Read More

refleXion

RefleXion Announces Real-World Evidence Outcomes Registry to Evaluate Treatment Impact on all Stages of Cancer

RefleXion's PREMIER registry has enrolled its first patient to gather real-world clinical evidence of the X1 machine. "Our prospective registry will capture and organize an unprecedented level of data including patient, demographic, tumor, biomarker, imaging and treatment information for all stages of cancer,” said Sean Shirvani, MD, MPH, chief medical officer at RefleXion.


Click to Read More


Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer

This recent study, conducted by the Peter MacCallum Cancer Centre, reviews biology-guided radiotherapy (BgRT) for metastatic prostate cancer. Through PET tracers that target prostate-specific membrane antigen (PSMA), BgRT uses these emissions to guide radiation therapy treatment. This study aims to describe nodal and distant metastasis distribution from prostate cancer and to determine the proportion of metastatic lesions suitable for BgRT.


Click to Read Article


Todd Powell Named to Top 50 Healthcare Technology CEOs of 2022

Todd Powell, RefleXion president and CEO, has been recognized in the Top 50 Healthcare Technology CEOs for 2022. Powell has successfully led commercialization of RefleXion’s first product, the RefleXion® X1, that has delivered over 2,500 patient treatments, while driving completion of its first clinical study and initiation of a real-world evidence clinical registry for patients with all stages of cancer.


Click to Read More

April 2022

Geisinger

Geisinger Debuts $80M Cancer Center Expansion

Geisinger held a ribbon cutting March 23 on an $80 million expansion to the cancer center at Geisinger Wyoming Valley Medical Center in Wilkes-Barre, Pa.

Click to Learn More

ViewRay

First Toxicity Results from SCIMITAR Prospective Phase II Trial Signal Favorable Toxicity Profile of Post-Prostatectomy Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer

Post-hoc Analysis Highlights Reduction in Gastrointestinal (GI) Toxicity with MRIdian® MRI-guided SBRT Compared to CT-guided SBRT, with No MRI-guided SBRT Patients Experiencing Grade 3 Genitourinary (GU) or Grade ≥2 Gastrointestinal Toxicity.

Click to Learn More

refleXion

RefleXion Raises $80 Million to Broaden Cancer Treatment Options

"The steadfast belief in RefleXion’s vision by our investor syndicate gives us the runway to drive hard and fast toward developing our platform for indications where radiotherapy was previously considered palliative only,” said Todd Powell, president and CEO of RefleXion.


Click to Learn More


RefleXion Dedicates The Sam Gambhir Memorial Learning Center After First Advisor

RefleXion is honored to dedicate its Clinician Learning Center and to rename it in honor of the late Sam Gambhir, MD, PhD. As the first scientific advisor to RefleXion, his impact and legacy will be long remembered.


Click to Learn More

Zap Surgical

Vive la France! Unicancer, representing 19 French cancer centers, selects the vault-free, cobalt-free ZAP-X as its preferred SRS platform.

Unicancer, a leading academic promoter of oncology clinical trials and medical equipment purchasing cooperative has selected ZAP-X as their SRS technology-of-choice for their member institutions.

Click to Learn More


ZAP announces multi-system order with Apollo Hospitals in India.

World-renowned hospital network to become the first provider in South Asia to offer ZAP-X Gyroscopic Radiosurgery, the latest advance in world-class radiosurgery.


Click to Learn More

Geisinger

HyperArc High-Definition Radiotherapy Achieves High Scores for Quality, Ease of Planning, and Workflow Efficiency

A recent study(1) comparing VMAT with HyperArc gave the latter high scores for quality, ease of planning, and workflow efficiency. The report covers nearly 700 patients treated over a 30-month period with single-isocenter SRS delivered on a Varian Edge® system and addressing some 2,000 targets. Find out more. (1) Popple RA, Brown MH, Thomas EM et al. Transition From Manual to Automated Planning and Delivery of Volumetric Modulated Arc Therapy Stereotactic Radiosurgery: Clinical, Dosimetric, and Quality Assurance Results, Practical Radiation Oncology, 11:2, March 2021, pages E163-E171.

Click to Learn More

March 2022

World-Class SRS in a Japanese Bullet Train Station – Setting New Standards in Patient Access and Convenience

ZAP Surgical recently announced installation of its pioneering vault-free, cobalt-free Gyroscopic Radiosurgery platform at the newly redeveloped Utsunomiya bullet train station in Japan’s Tochigi Prefecture. The new installation brings advanced radiosurgery to an entirely new, more cost-effective setting outside of the large urban hospital.

Click to Learn More

February 2022

ZAP Surgical Inspires Expansion of Novel Non-Invasive Brain Tumor Procedures to Unique Suburban Settings

A sea change in how and where world-class radiosurgery is delivered. Large academic hospitals are expanding SRS to new, lower cost locations: suburban and rural community hospitals, as well as innovative outpatient settings (e.g. a bullet train station in Japan). Read the full article and interesting community discussions.


Click to Learn More


New ZAP-X Publication from Barrow Neurological Institute

An informative ZAP-X case series from Barrow Neurological Insitute. 59 patients spanning a comprehensive mix of meningioma, metastases, glioma, schwannoma, and pituitary tumor SRS cases.


Click To Learn More

RefleXion Introduces New Scientific Advisory Board

“Since cancer care is multidisciplinary, it made sense to establish a scientific advisory board with deep and broad knowledge across multiple specialties,” said Sean Shirvani, MD, RefleXion’s chief medical officer. Meet the medical experts on our new scientific advisory board.


Meet the New Scientific Advisory Board


ViewRay Receives 510(k) Clearance on Next Generation of MRIdian MRI-Guided Radiation Therapy Features

MRIdian A3i and Brain Treatment Package Enhance On-Table Adaptive Workflow and Expand Clinical Utility


Click To Learn More

January 2022


ViewRay Receives 510(k) Clearance on Next Generation of MRIdian MRI-Guided Radiation Therapy Features

ViewRay, Inc. (NASDAQ: VRAY) announced that the company received FDA 510(k) clearance for its next generation of MRI-guided radiation therapy features, focused on enhancing on-table adaptive workflow and expanding clinical utility. MRIdian A3i includes a suite of new features to streamline on-table adaptive workflow and provide the potential to reduce treatment times, along with a new brain treatment package expanding clinical utility into cranial stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT).


Click To Learn More

World Class Dosimetry, Remarkable Throughput

Congratulations to Dr. Alexander Muacevic and the team at European Radiosurgery Center Munich for having recently treated 50 SRS patients with the ZAP-X Gyroscopic Radiosurgery platform in just a few short months. A beautiful center delivering world-class medicine.


Click to Learn More


ZAP-X Planning Study: Temporoparietal AVM

See how the vault-free, cobalt-free ZAP-X® Gyroscopic Radiosurgery® platform delivers an exceptionally low V12 to normal brain tissue with an extraordinarily sharp dose gradient.


Click To Request the Study


RefleXion X1 Headed to UPMC

Another RefleXion X1 recently left the factory heading to University of Pittsburgh Medical Center. They will be among the first to deliver biology-guided radiotherapy (BgRT)* utilizing the cancer itself to guide radiation delivery, even in tumors that are moving. The technology uses PET to guide personalized radiotherapy.

*The RefleXion™ X1 is cleared for SBRT/SRS/IMRT treatments. BgRT is limited by U.S. law to Investigational use.


Click To Learn More


RefleXion Founder Awarded 2021 Engineering Alumni Achievement Medal

Sam Mazin, founder and CTO of RefleXion, is the winner of the 2021 Faculty of Engineering Alumni Achievement Medal from his alma mater the University of Waterloo. This award honors alumni who have distinguished themselves through professional achievements, community service or academic excellence.


Click To Learn More


New Podcast! RefleXion and HealthMyne Partner to Advance Personalized Care

Rose Higgins, chief executive officer at HealthMyne, Inc., sits down with Sam to discuss the role radiomics is playing in cancer care. Our biology-guided radiotherapy will generate a plethora of new data that will one day become part of the data fabric to help us understand what is happening at both the molecular and biological level. This podcast dives into how radiomics can provide insights to better inform treatment decisions and what the future may hold.


Click To Listen


ZAP Surgical Appoints Industry Veterans to Lead Chinese Market Expansion

ZAP Kicks Off Chinese Market Expansion. Chinese Trials Concluded, NMPA Clearance Expected Soon.


Click To Learn More


The First ZAP-X in Colorado, Installation Underway!

Congratulations to the team at Neurosurgery One and Littleton Adventist Hospital.


Click To Learn More

ViewRay Announces MRIdian MR-Guided Radiation Therapy Surpasses 2,300 Pancreatic Cancer Patients Treated Worldwide

With 46 Centers in 16 Countries, Clinical Teams are Changing the Paradigm for Pancreatic Cancer with MRIdian.


Click to Learn More

Accuray CyberKnife® Robotic Radiotherapy Platform Expands Range of Neurological Indications That Can Be Effectively Treated With Stereotactic Radiosurgery

7,000 Patient Single Institution Analysis Shows Safety, Versatility and Increasing Use of the Advanced Radiotherapy Platform Over a 20-Year Timeframe.


Click to Learn More

RefleXion Receives Breakthrough Device Designation for Lung Cancer Treatment

The U.S. Food and Drug Administration (FDA) has granted RefleXion Breakthrough Device Designation for its biology-guided radiotherapy* (BgRT) for use in treating lung tumors. The breakthrough potential of BgRT lies in its ability to detect and then immediately treat moving tumors. It is the first and only technology to use injected radiotracers to produce active signals, called emissions, from each tumor to guide treatment delivery.


Click to Learn More

November 2021



ZAP Surgical to Bring Next-Gen Non-Invasive Brain Tumor Treatment to the American Hospital of Paris Group

Centre de Cancérologie de la Porte de Saint-Cloud is to become the first in France to offer ZAP-X Gyroscopic Radiosurgery.


Click To Learn More

Accuray CyberKnife Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients

Accuray Incorporated announced that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.


Click to Learn More


New Outcomes Data Demonstrating Prolonged Survival for Inoperable Pancreatic Cancer Patients Presented at Leading Radiation Oncology Meeting

Findings Show Median Overall Survival Of 26 Months for Patients Receiving Ablative Doses with MRIdian MRI-Guided Radiation Therapy.


Click To Learn More

October 2021



Coming Soon: The First ZAP-X in Spain

The new Institute of Advanced Radiosurgery at the Viamed Virgen de la Paloma Hospital in Madrid to soon offer the next generation of stereotactic radiosurgery.

Click To Learn More


Academic Congresses Return!

ZAP is extremely proud to sponsor the 2021 Congress of Neurological Surgeons (CNS) meeting, Oct 16-20, in Austin, TX.

Stop by booth #1749 to experience ZAP-X in Augmented Reality - and see for yourself how ZAP is boldly going where no SRS system has gone before.


Click To Learn More


ZAP-X Complex Meningioma Treatment Planning Study

See how the vault-free, cobalt-free ZAP-X® Gyroscopic Radiosurgery® platform delivers an exceptionally sharp dose gradient with remarkably low dose to the cochlea and healthy brain.

Click To Request the Study

ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations

New suite of workflow and clinical features to be highlighted at upcoming ASTRO 2021 conference.


Click to Learn More

September 2021



Trigeminal Neuralgia Treatment Planning Study

Trigeminal neuralgia is often considered the most demanding of all SRS procedures. Combined with rapid planning and delivery times, see how the ZAP-X delivers an exceptionally sharp dose gradient with a remarkably low dose to the brainstem.



Request the Study

UAB Adds Personalized Touch to Cancer Treatment with Adaptive Radiation

Story by Bob Shepard

They are calling it radiation oncology’s contribution to personalized medicine. Adaptive radiation — called by some the holy grail of radiation therapy — has come to the University of Alabama at Birmingham O’Neal Comprehensive Cancer Center in the form of the newest radiation delivering tool, a linear accelerator system called Ethos from Varian.



Read More

August 2021



First Patients Treated in Munich

Dr. Alexander Muacevic and the European Radiosurgery Center Munich had a productive first week of clinical SRS treatments. 2 meningiomas, 2 acoustic neuromas, and a multiple brain mets patient in the first 2 days. Remarkable!



Read More

ViewRay Announces First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic Cancer

Study to Explore Clinical Benefits of Precise, High Dose Radiation Therapy Enabled by MRIdian's MR-guidance Combined with Daily On-table Adaptation in Pancreatic Cancer.


Read More

July 2021



SRS Investment 'Future Proofed' with ZAP-X

With continuing pressure from the IAEA to abolish the use of radioactive sources, the cobalt-free ZAP-X at the Swiss Neuro Radiosurgery Center (SNRC) has ensured the long-term viability of their SRS investment. SNRC initiated first patient treatments on June 16, 2021.

Read More


Renowned SRS Provider Breaks Ground with Vault-Free ZAP-X Installation

Considered among the most accomplished radiosurgery providers in the world, neurosurgeon Alex Muacevic and the European CyberKnife Center in Munich recently commenced installation of its ZAP-X Gyroscopic Radiosurgery platform.

Read More


Mitigating the Risks of Cognitive Deficit

With regional recurrence rates post-SRS ranging from 67% to 76%, minimal mean whole brain dose is a critical enabler for future potential radiosurgical re-treatment. A recent multiple mets ZAP-X study demonstrated exceptionally low mean whole brain dose and 100% target coverage using 0 mm PTV margins - not to mention, remarkably rapid planning and delivery times.

Read More

UPMC Hillman Cancer Center Among First in Country to Offer Radiotherapy That Lets Tumors Guide Treatment

UPMC Hillman Cancer Center will be the first cancer center in the eastern United States, and one of just a handful in the country, to offer the most advanced radiotherapy system for treating patients.

The RefleXion™X1 is the world’s first biology-guided radiotherapy (BgRT) machine that’s expected to improve treatment and expand options for patients with metastatic disease, where few treatments are currently available.


Read More

Elekta Harmony Receives FDA Approval

Elekta received FDA clearance for a new linear accelerator called Elekta Harmony. Elekta Harmony is built for productivity, versatility and precision and features the new FastTrack workflow experience.


Read More